Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 405Brain Neoplasms 163Glioma 159Gliosarcoma 128Astrocytoma 115Central Nervous System Neoplasms 110Oligodendroglioma 74Neuroblastoma 44Medulloblastoma 33Ependymoma 26Recurrence 23Neoplasms 19Neoplasm Metastasis 16Diffuse Intrinsic Pontine Glioma 15Choroid Plexus Neoplasms 13Optic Nerve Glioma 11Melanoma 11Spinal Cord Neoplasms 10Rhabdoid Tumor 10Lymphoma 9Familial ependymoma 9Rhabdomyosarcoma 8Osteosarcoma 8Neuroectodermal Tumors, Primitive 8Breast Neoplasms 8Sarcoma, Ewing 6Sarcoma 6Pinealoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Glioma, Subependymal 6

Interventions

sodium thiosulfate 3Filgrastim 3Carboplatin 3etoposide phosphate 2Cyclophosphamide 2pegfilgrastim 1Vincristine 1Trastuzumab 1Temozolomide 1Rituximab 1Procarbazine 1Methotrexate 1Mannitol 1Lomustine 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Genetic Therapy 1Etoposide 1Cytarabine 1Cefixime 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Temozolomide × CNS × Clear all
NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
30 enrolled
CNS

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡